Skip to main content
Evidence Snapshot

Acetylcholinesterase

CHEMBL4780 SINGLE PROTEIN Torpedo californica
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T16:46:51Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4780
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Acetylcholinesterase as ChEMBL target CHEMBL4780, mapped to UniProt P04058. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Acetylcholinesterase
SINGLE PROTEIN · Torpedo californica
As of 2026-09-13
ChEMBL target ID
CHEMBL4780
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P04058
Acetylcholinesterase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Acetylcholinesterase matters

As of 2026-09-13

Acetylcholinesterase is reviewed as Acetylcholinesterase (UniProt P04058); the current evidence base includes 13 approved drugs, 395 compounds, and 91 assays, with lead potency reaching pChEMBL 10.8.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 13 approved drugs, 395 compounds, and 91 assays for this target. The dominant activity type is IC50. CHEMBL525622 is the current potency anchor at pChEMBL 10.8.

Use CHEMBL525622 as the tractability anchor when discussing potency (pChEMBL 10.8).

Activity source · ChEMBL 36 via Core Engine
13 approved pChEMBL 10.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Acetylcholinesterase matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P04058, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

395
Total Compounds
91
Total Assays
13
Approved Drugs
IC50: 436.0, KI: 60.0, KD: 4.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL525622
 10.8 Ki —
No preferred name
CHEMBL606348
 10.7 IC50 —
No preferred name
CHEMBL594870
 10.6 IC50 —
No preferred name
CHEMBL596236
 10.4 IC50 —
No preferred name
CHEMBL593933
 10.3 IC50 —

Approved Drugs

Structure Compound First Approval
NEOSTIGMINE
CHEMBL278020
 2013
GALANTAMINE
CHEMBL659
 2001
DONEPEZIL HYDROCHLORIDE
CHEMBL1678
 1996
DONEPEZIL
CHEMBL502
 1996
IRINOTECAN
CHEMBL481
 1996
TACRINE
CHEMBL95
 1993
PYRIDOSTIGMINE
CHEMBL1115
 1955
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T16:46:51Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4780